Remus
Dedicated to Global Healthcare

November 09, 2024

To,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Submission of statement of Deviation or Variation for proceeds of public issue pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on September 30, 2024

With reference to the captioned subject, please find enclosed a Statement (annexed as Annexure-A) confirming that there were no deviation(s) or variation(s) in the use of proceeds of public issue, pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on September 30, 2024. The said statement was reviewed by the Audit Committee in their meeting held on November 09, 2024.

We hereby request you to take the above information on record.

Thanking you
Yours Sincerely,
For, Remus Pharmaceuticals Limited

DEVAL BAKULKUMAR PATEL
Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2024.11.09 15:15:32 +05'30'

REMUS PHARMACEUTICALS LTD
AHMEDABAD

Deval Patel
Company Secretary & Compliance Officer
Membership No.: A60090

Encl.: As Above

Remus Pharmaceuticals Limited
REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857
E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Remus
Dedicated to Global Healthcare

Annexure – A

Statement of Deviation / Variation in utilisation of funds raised

<table>
<tr><td>Name of listed entity</td><td colspan="6">Remus Pharmaceuticals Limited</td></tr>
<tr><td>Mode of Fund Raising</td><td colspan="6">Initial Public offer</td></tr>
<tr><td>Date of Raising Funds</td><td colspan="6">Issue Opening Date- May 17, 2023
Issue Closing Date- May 19, 2022
Date of Allotment- May 24, 2023
Listing Date- May 29, 2023</td></tr>
<tr><td>Amount Raised</td><td colspan="6">Rs. 4768.52 Lakhs</td></tr>
<tr><td>Report filed for Quarter ended</td><td colspan="6">September 30, 2024</td></tr>
<tr><td>Monitoring Agency</td><td colspan="6">Not Applicable</td></tr>
<tr><td>Monitoring Agency Name, if applicable</td><td colspan="6">Not Applicable</td></tr>
<tr><td>Is there a Deviation / Variation in use of funds raised</td><td colspan="6">No</td></tr>
<tr><td>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</td><td colspan="6">Not Applicable</td></tr>
<tr><td>If Yes, Date of shareholder Approval</td><td colspan="6">Not Applicable</td></tr>
<tr><td>Explanation for the Deviation / Variation</td><td colspan="6">Not Applicable</td></tr>
<tr><td>Comments of the Audit Committee after review</td><td colspan="6">None</td></tr>
<tr><td>Comments of the auditors, if any</td><td colspan="6">None</td></tr>
<tr><td>Objects for which funds have been raised and where there has been a deviation, in the following table</td><td colspan="6">Objects of issue (as stated in Prospectus dated May 23, 2023)
1. To Meet Working Capital Requirements
2. Funding investments for acquisitions and general corporate purposes
3. To meet Public Issue Expenses</td></tr>
<tr><td>Original Object</td><td>Modified Object, if any</td><td>Original Allocation</td><td>Modified Allocation, if any</td><td>Funds Utilised</td><td>Amount of Deviation/Variation for the quarter according to applicable object</td><td>Remarks if any</td></tr>
<tr><td colspan="7">Not applicable as no deviation from the objects</td></tr>
</table>

Remus Pharmaceuticals Limited
REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857
E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

Remus
Dedicated to Global Healthcare

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised; or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or

(c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536